Enanta Pharmaceuticals, Inc. (ENTA) Reaches $110.69 After 7.00% Down Move; Alkermes PLC Has 1.15 Sentiment

June 14, 2018 - By reb123z

Alkermes PLC (ALKS) investors sentiment increased to 1.15 in Q1 2018. It’s up 0.40, from 0.75 in 2017Q4. The ratio is positive, as 102 investment professionals opened new and increased stock positions, while 89 cut down and sold holdings in Alkermes PLC. The investment professionals in our database now possess: 152.74 million shares, up from 152.34 million shares in 2017Q4. Also, the number of investment professionals holding Alkermes PLC in top ten stock positions increased from 1 to 2 for an increase of 1. Sold All: 17 Reduced: 72 Increased: 61 New Position: 41.

The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a huge mover today! The stock decreased 2.42% or $2.74 during the last trading session, reaching $110.69. About 149,776 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 217.72% since June 14, 2017 and is uptrending. It has outperformed by 205.15% the S&P500. Some Historical ENTA News: ; 08/05/2018 – ENANTA PHARMACEUTICALS INC – ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MLN DUE TO INCREASE IN ABBVIE’S MAVYRET SALES; 08/05/2018 – Enanta Pharmaceuticals 2Q Rev $44M; 24/04/2018 – Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second; 14/05/2018 – Stonepine Capital Management LLC Exits Position in Enanta; 21/05/2018 – Enanta at JMP Securities Life Sciences Conference Jun 20; 14/05/2018 – Janus Henderson Group Buys New 2.6% Position in Enanta; 08/05/2018 – Enanta Pharmaceuticals 2Q EPS 61c; 19/03/2018 Enanta at Investor Day Hosted By H.C. Wainwright Today; 28/03/2018 – Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018; 09/05/2018 – ENANTA PHARMACEUTICALS INC ENTA.O : RBC RAISES TARGET PRICE TO $100.00 FROM $80The move comes after 7 months negative chart setup for the $2.13B company. It was reported on Jun, 14 by Barchart.com. We have $102.94 PT which if reached, will make NASDAQ:ENTA worth $149.31 million less.

Since March 19, 2018, it had 0 insider buys, and 5 sales for $6.03 million activity. 4,155 shares valued at $437,333 were sold by Adda Nathalie on Wednesday, May 16. Luly Jay R. had sold 25,000 shares worth $2.65 million. The insider MELLETT PAUL J sold 15,000 shares worth $1.81M.

Among 8 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Enanta Pharmaceuticals Inc has $135 highest and $16 lowest target. $72.29’s average target is -34.69% below currents $110.69 stock price. Enanta Pharmaceuticals Inc had 27 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Hold” on Friday, September 15. RBC Capital Markets maintained the shares of ENTA in report on Wednesday, April 4 with “Hold” rating. Oppenheimer initiated the shares of ENTA in report on Thursday, June 7 with “Buy” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, January 2. JMP Securities upgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Friday, October 23. JMP Securities has “Mkt Outperform” rating and $32 target. The rating was downgraded by J.P. Morgan to “Hold” on Thursday, February 8. As per Thursday, February 8, the company rating was downgraded by JP Morgan. The stock has “Buy” rating by TheStreet on Saturday, August 8. The rating was maintained by Robert W. Baird on Monday, November 20 with “Hold”. The firm earned “Underweight” rating on Friday, October 23 by Barclays Capital.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $2.13 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 63.22 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” on June 12, 2018, also Businesswire.com with their article: “Enanta Pharmaceuticals Recognizes the 1st International NASH Day” published on June 12, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 06, 2018. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Intercept’s Obeticholic Acid Therapy And NASH: The Scientific Truth Is That Every Cloud Has A Silver Lining” published on June 13, 2018 as well as Seekingalpha.com‘s news article titled: “Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?” with publication date: June 01, 2018.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on August, 6. They expect $0.94 EPS, up 313.64% or $1.38 from last year’s $-0.44 per share. ENTA’s profit will be $18.11M for 29.44 P/E if the $0.94 EPS becomes a reality. After $0.61 actual EPS reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 54.10% EPS growth.

Investors sentiment increased to 1.66 in 2018 Q1. Its up 0.08, from 1.58 in 2017Q4. It improved, as 11 investors sold Enanta Pharmaceuticals, Inc. shares while 45 reduced holdings. 42 funds opened positions while 51 raised stakes. 14.18 million shares or 4.00% more from 13.64 million shares in 2017Q4 were reported. Eqis Cap Mgmt owns 31,627 shares. Proshare Advsr Limited Liability Corp reported 11,286 shares. Strs Ohio stated it has 11,700 shares or 0% of all its holdings. Employees Retirement Sys Of Ohio reported 13,586 shares or 0.01% of all its holdings. Matarin Cap Ltd has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 223,507 shares. Thrivent Financial For Lutherans holds 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 9,299 shares. Louisiana State Employees Retirement holds 0.02% or 6,400 shares. Krensavage Asset Limited Com owns 739,738 shares or 14.52% of their US portfolio. Illinois-based Guggenheim Cap Ltd Liability has invested 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Tiaa Cref Mgmt Ltd Company has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 38,717 shares. California-based California Pub Employees Retirement Systems has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Goldman Sachs stated it has 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Dekabank Deutsche Girozentrale invested in 0% or 4,500 shares. Schwab Charles Inv Management holds 0.01% or 91,494 shares in its portfolio. Bridgeway Cap Management accumulated 23,200 shares or 0.02% of the stock.

Meditor Group Ltd holds 9.4% of its portfolio in Alkermes plc for 1.03 million shares. Opus Point Partners Management Llc owns 24,333 shares or 2.77% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 1.69% invested in the company for 60,536 shares. The New Mexico-based Thornburg Investment Management Inc has invested 1.37% in the stock. Timpani Capital Management Llc, a Wisconsin-based fund reported 59,311 shares.

Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on July, 26. They expect $-0.28 EPS, down 115.38% or $0.15 from last year’s $-0.13 per share. After $-0.20 actual EPS reported by Alkermes plc for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $7.83 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

The stock increased 3.09% or $1.515 during the last trading session, reaching $50.505. About 521,087 shares traded. Alkermes plc (ALKS) has declined 21.00% since June 14, 2017 and is downtrending. It has underperformed by 33.57% the S&P500. Some Historical ALKS News: ; 23/05/2018 – Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology; 26/04/2018 – Alkermes 1Q Rev $225.2M; 02/04/2018 – ALKERMES GETS REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461; 02/04/2018 – After a preliminary review, the U.S. Food and Drug Administration determined it had insufficient evidence for the drug’s effectiveness and is “unable to complete a substantive review,” according to a release from Alkermes; 08/05/2018 – Alkermes at Deutsche Bank Health Care Conference Tomorrow; 26/04/2018 – Alkermes Sees 2018 Loss $210M-Loss $240M; 02/04/2018 – Alkermes Receives Refusal To File Letter From FDA For ALKS 5461; 16/04/2018 – ALKERMES PLC – FDA ACTION EXPECTED BY JAN. 31, 2019; 26/04/2018 – Alkermes Sees 2018 VIVITROL Net Sales of $300M-$330M; 26/04/2018 – Alkermes Expects 2018 R&D Expenses of $415M-$445M

More notable recent Alkermes plc (NASDAQ:ALKS) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 06, 2018, also Streetinsider.com with their article: “Alkermes (ALKS) Receives $50M Payment From Biogen (BIIB) Following Review of Prelim. Data From Ongoing …” published on June 06, 2018, Seekingalpha.com published: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018. More interesting news about Alkermes plc (NASDAQ:ALKS) were released by: Globenewswire.com and their article: “Detailed Research: Economic Perspectives on Bank of Nova Scotia, Eaton Corporation, Canadian National Railway …” published on June 04, 2018 as well as Benzinga.com‘s news article titled: “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: June 07, 2018.

Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 38.60% above today’s ($50.505) share price. ALKS was included in 3 notes of analysts from October 21, 2016. The firm has “Overweight” rating by JP Morgan given on Friday, October 21. The company was maintained on Friday, October 21 by Jefferies. As per Friday, October 21, the company rating was maintained by Leerink Swann.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: